Investigational Drug Information for TL-895

« Back to Dashboard

What is the drug development status for TL-895?

TL-895 is an investigational drug.

There have been 7 clinical trials for TL-895. The most recent clinical trial was a Phase 1 trial, which was initiated on October 22^nd 2020.

The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, and Lymphoma, B-Cell. The leading clinical trial sponsors are Telios Pharma, Inc., Kartos Therapeutics, Inc., and Merck KGaA.

There are fourteen US patents protecting this investigational drug and seventy-four international patents.

Summary for TL-895

US Patents	14
International Patents	74
US Patent Applications	39
WIPO Patent Applications	12
Japanese Patent Applications	4
Clinical Trial Progress	Phase 1 (2020-10-22)
Vendors	26

Recent Clinical Trials for TL-895

Title	Sponsor	Phase
Phase 1b/2 Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib	Telios Pharma, Inc.	Phase 1/Phase 2
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis	Kartos Therapeutics, Inc.	Phase 2
TL-895 and KRT-232 Study in Acute Myeloid Leukemia	Kartos Therapeutics, Inc.	Phase 1/Phase 2

See all TL-895 clinical trials

Clinical Trial Summary for TL-895

Top disease conditions for TL-895

Top clinical trial sponsors for TL-895

See all TL-895 clinical trials

US Patents for TL-895

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
TL-895		Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity	Merck Patent GmbH (Darmstadt, DE)
TL-895		Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors	Janssen Pharmaceutica NV (Beerse, BE)
TL-895		Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity	Merck Patent GmbH (Darmstadt, DE)
TL-895		Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity	Merck Patent GmbH (Darmstadt, DE)
TL-895		Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity	Merck Patent GmbH
TL-895		Methods of treating splenomegaly	Telios Pharma Inc

International Patents for TL-895

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
TL-895	Australia	AU2012267491	2031-06-10
TL-895	Australia	AU2017235978	2031-06-10
TL-895	Brazil	BR112013030442	2031-06-10
TL-895	Canada	CA2833771	2031-06-10
TL-895	China	CN103814016	2031-06-10
TL-895	China	CN106831732	2031-06-10